Making a decision about disclosure involved balancing the needs of decision makers with commercial/legal implication

Drivers

- Customer demand UK driven
- Credibility of available information
- Consistency with values of partnership
- Ensures inclusion of trials in evidence based decision making

Concerns

- Release of commercially sensitive information
- Use of information by competitors
- Resource implications particularly if retrospective
- Lack of relevance outside the UK

Against this background Glaxo Wellcome & Schering UK have made the decision to develop/input into Clinical Trial Registers - the rest of the industry is still undecided